Bioengineers from the Duke University have evolved a simplistic and cost-effectual means to load cancer drug consignments into nano-level release mediums and exhibited in animal models that this novel nano-formulation could eradicate tumors following a solo treatment. Subsequent to conveying the drug to the tumor, the delivery medium disperses into undamaging by-products, thus distinctly lowering the toxicity for the receiver.

Nano-release systems are turning out to be progressively more eye-catching to scientists due to their capacity of effectually getting within the tumors. Due to the permeable nature of the blood vessels that supply the tumors as compared to the normal vessels, the nano-formulation could more readily gain entry and amass inside the tumour cells. This translates to the fact that increasing dosages of the drug could be conveyed, enhancing its cancer-combating capacities while lowering the side effects linked to systematic chemotherapy.

The scientists explicated that when the novel formulation was employed for delivering cancer-combatant drugs in their models it had a four times greater maximum accepted dosage as compared to the analogous drug used on its own, and it was observed to induce almost total tumor degeneration following a solo jab. The free drug has simply a reserved outcome in shrivelling the tumors or in extending animal survival.

The outcomes of this research had been available early online in the ‘Nature Materials’ journal. Different from other approaches, the scientists were able to create vast amounts easily and cost-effectively and the novel approach in theory could be employed for enhancing the efficacy of other existent cancer medicines.

The fundamental part of this novel approach is the way in which the drug latches on to its polypeptide conveyance system and whether or not the drug would be water-soluble.

The delivery system employs the bacterium Escherichia coli or E.coli that has been heritably modified for producing synthetic polypeptide called as chimeric polypeptide. As E.coli are prevalently employed for producing proteins, it makes for a simplistic and dependable creation plant for such definite polypeptides with elevated yield.

As soon as it latches on to one of such chimeric polypeptides, the drug dons the features that drug single-handedly fails to have. Majority of the drugs fail to be water-soluble that restricts their capacity to be absorbed by the cells. However being latched on to the nanoparticle makes it dissolvable in water.

When these two constituents are merged in a container, they instinctively self-amass into a water-dissolvable nanoparticle. They additionally self-accrue every time and dependably in a range of fifty nanometers or so which makes them idyllic for cancer treatment. As several chemotherapy drugs do not dissolve, hence this novel approach had the capacity to work is such cases.

The newest research employed doxorubicin, a widely utilised agent for treating cancers inflicting the blood, breasts, ovaries and other organs of the body. The scientists infused the mice with tumors that were embedded sub-dermally with either the chimeric polypeptide- doxorubicin combo or solely doxorubicin.

The mice that underwent treatment with solely doxorubicin showed tumor size averaging twenty-five times bigger as compared to those that underwent treatment with the novel blend. The average survival time period for the mice treated with doxorubicin was about twenty-seven days in comparison to more than sixty-six days in mice that were administered the novel formulation.

The Duke scientists are presently planning to examine the novel blend on varying forms of cancer, alongside tumors that are proliferating inside diverse organs of the body. They would additionally attempt to coalesce these chimeric polypeptides with other non-dissolvable drugs and check their efficacy against tumors.

Treatment is not always required for individuals having hairy cell leukemia as this type of cancer has a slow progression rate and at times does not advance at all, some individuals would rather follow the wait and watch policy and prefer getting treated solely after they start becoming symptomatic. The major populace of individuals having hairy cell leukemia would ultimately require treatment.

Though one might be keen to free one’s body of any malignancy following diagnosis with hairy cell leukemia, there are no benefits of early treatment. In contrast to few other forms of cancer, hairy cell leukemia is relatively curable in all stages, translating to the fact that remission would not be any lesser if one adopted the wait and watch approach for treatment.

In case the presence of hairy cell leukemia is making a person symptomatic, then one could opt for undergoing treatment. Though hairy cell leukemia has no cure, still the bright aspect is that novel treatments are effectual in putting the disease in remission phase for several years.

Chemotherapy

Doctors have pegged the employment of chemotherapy drugs as the preliminary line of treatment for hairy cell leukemia. The vast populace of individuals would undergo a total or incomplete remission all through the chemotherapy course. The two kinds of chemotherapy drugs employed for treatment of hairy cell leukemia are:

• Cladribine (Leustatin)
  Majority of the treatment schedules for hairy cell leukemia start with cladribine. The patient would be given a continuous intravenous administration of the drug over a span of a week’s time. A total remission lasting for many years is often the case with majority of the individuals undergoing treatment with cladribine. In case hairy cell leukemia relapses, then re-treatment with cladribine is the course of therapy. Side effects experienced due to cladribine are infection and fever.
• Pentostatin (Nipent)
  Pentostatin has analogous remission rates as that of cladribine, however it is offered on a different regimen. Patients are given intravenous infusions of pentostatin every alternate week that would be continued till 6 months. The side effects due to pentostatin involve fever, infection, overly sensitive to light, inflammation in the eyes (keratoconjunctivitis), nausea and puking.

A small populace of individuals having hairy cell leukemia show resistance to chemotherapy meaning that they would fail to attain remission following the use of these drugs. Other individuals cannot take chemotherapy. For example, those having infections should steer clear from chemotherapy as these drugs repress the immune system and could worsen the existent small infections.

Biological Treatments (Immunotherapy)

Biological therapy or immunotherapy aims at making cancer cells more identifiable to the immune system. As soon as the immune system detects the cancer cells as offenders, it could start the annihilation process. The two kinds of biological treatments employed for treating hairy cell leukemia are:

• Alpha-interferon
  Alpha-interferon was the foremost biological drug that has garnered approval for cancer treatment. Alpha-interferon is generally suggested when chemotherapy has proven ineffectual or one is incapable of taking chemotherapy. Major populace of individuals treated with alpha-interferon taken over a span of a year have incomplete remission. Side effects faced are flu-similar signs like fever and exhaustion.
• Rituximab (Rituxan)
  Rituximab is a monoclonal antibody that has got approval for treatment of non-Hodgkin’s lymphoma, though it is at times employed in treating hairy cell leukemia. In case chemotherapy drugs failed to work or one cannot undergo chemotherapy, then the doctor could suggest rituximab. Side effects of rituximab involve bleeding, weariness, headaches and infection.

Surgery

Surgery for spleen removal (splenectomy) was the preliminary line of treatment employed for treating hairy cell leukemia, although it is used on occasional basis now-a-days. The doctor would suggest splenectomy in case there is a rupture or enlargement of the spleen and leading to pain or discomfort. Though removal of the spleen does not cure hairy cell leukemia, it could generally reinstate the normal blood counts. Hence due to this reason, splenectomy could be beneficial for individuals ailing from uninhibited infections. All surgical procedures have a risk of blood loss and infection. Spleen removal could lead to blood vessel inflammation (vasculitis) making one more prone to infection.

The novel pill –dubbed PLX4032 was observed to contract tumors in seventeen out of twenty-seven patients having advanced stage melanoma that were administered the pill. In the case of 2 of those patients, there was total disappearance of the tumors.

The MD of Memorial Sloan-Kettering Cancer Center, New York stated that the outcome has been exceptional. He explicated that in one patient who had undergone the prior-to and subsequent imaging scans, there was complete healing of the tumor. He mentioned that this was the first instance he had observed anything as spectacular as this.

Chapman further added how the signs of the tumors fading away in a span of 2 weeks became evident to them.

By and large, there was seventy percent shrinkage of the tumor in patients that had a specific form of cancer-associated mutation who were administered the pill.

Contrarily, chemotherapy drugs employed for treating advanced melanoma aided in shrivelling tumors by a meagre fifteen percent, Chapman stated.

The novel pill was easily stomached by the patients and no patients appeared to drop out because of any kind of side effects.

The discovery was put forward at the joint convention of the European Cancer Organization or ECCO and the European Society of Medical Oncology.

Melanoma is the most lethal kind of skin cancers, with nearly 1,60,000 newly cropping cases detected globally every year. It could be treated when spotted early, however once it metastasizes or spreads, there is rarely any kind of cure and usually has fatal outcome in a year’s time.

The American Cancer Society has stated that in the present year there have been an approximate 68,720 newly detected cases and 8,650 fatalities due to the disease in the United States.

The new-fangled drug inhibits the activity of the gene known as BRAF that is the offender in nearly fifty to sixty percent of the melanoma cases.

The President of the ECCO Alexander Eggermont, MD, states that the outcome was truly magnificent.

Previous research has revealed that patients that didn’t have a mutated BRAF gene didn’t react to the drug. The present drug is target-specific that seems to make it more workable.

Chapman and his associates have planned to undertake a study that would involve ninety patients scheduled for the ending part of 2009 and a bigger-sized global trial that would involve hundreds of entrants is planned in the initial part of 2010.

Plexicon, the manufacturer of the novel drug has licensed it to Roche, backed the research work.

Leukaemia is the cancer caused due to the uninhibited proliferation of the white blood cells due to which these cells cannot reach maturity.

In acute lymphoblastic leukemia, there is unrestrained production of the immature lymphocytes known as lymphoblasts (at times called as blast cells). There are two varied kinds of lymphocytes, namely: B-lymphocytes and T-lymphocytes.

These immature cells inundate the bone marrow and impede proper functioning of blood cells production. Since the leukemia cells have not attained total maturity, they fail to carry out the task of normal white blood cells leading to a heightened likelihood of infections. As the bone marrow is crammed with immature white blood cells, it cannot produce adequate amounts of healthy red cells and platelets.

ALL is more prevalent among children below the age of fifteen years as compared to adults. When detected in teen years or among adults, ALL is more frequent in those individuals lying in the age band of 15-25 years and in elderly persons. It is more commonly detected in men as compared to women.

On the basis of the WHO system, ALL is classified on the basis of the lymphocyte type (B- or T-lymphocyte) that has turned malignant, into three varied sub-types:

• Early (precursor) B-lymphoblastic leukemia (majority of the adults detected with ALL are believed to be having this type)
• Mature B-lymphoblastic leukemia (at times known as Burkitt-type ALL as it is alike Burkitt syndrome)
• Early (precursor) T-lymphoblastic leukemia.

Acute Lymphoblastic Leukaemia Causes and Risk Factors:

There is ongoing research to understand the cause of ALL. ALL, like other cancer types, is non-contagious.

Studies have revealed that the risks of getting acute lymphoblastic leukemia are not augmented due to:

• Being exposed to electromagnetic fields.
• Residing close to high-voltage electricity cables.
• Radon presence in households.

There are several risk factors that could raise the chances of developing ALL, namely:

• Radiation – Being exposed to soaring levels of radiation, for instance, in the event of a nuclear accident or an atom bomb. Increasing number of leukemia cases have been observed among those residing near nuclear power plants.
• Genetic Constitution – ALL is mostly not the outcome of an inherited flawed gene. However, those with particular heritable disorders inclusive of Down’s syndrome and Fanconi’s anaemia have been observed to be at a heightened risk of developing leukemia.
• Chemical Exposure – In atypical cases, leukemia might be cited in those that have had exposure to chemicals like benzene and other kinds of solvents that are utilised for industrial purposes.
• Infection – ALL is believed to be caused due to the chain of genetic variations in a certain group of under-developed blood cells. It is still unclear as to the causes behind these genetic variations, but infection might be playing a significant part in the process. Though, no definite infections that lead to leukemia have been detected.

Acute Lymphoblastic Leukaemia Symptoms:

• Sense of paleness occurring due to anaemia caused because of the dearth of red blood cells.
• Tiredness, breathlessness in spite of no major exertion.
• A general sense of unwell and feeling below par, possibly due to throat or mouth soreness.
• Joint and bone aches. The bones might be affected due to leukemia cells.
• Recurrent infections due to the dearth of healthy white blood cells that lowers immunity.
• Abnormal bleeding – This could occur due to lowered platelet count. This could include bruises appearing without any evident injury, heavy menstrual cycles among women, gums that bleed easily and recurrent nose bleeds.

On certain occasions, an individual would be asymptomatic and leukemia is detected only during the routine blood analysis.

Signs of acute lymphoblastic leukemia might occur swiftly in some weeks and prompt treatment might become necessary.

Diagnosis & Tests:

• An abnormal outcome of a blood test could point to the presence of ALL. In such a situation the haematologist specialising in treating blood problems would order visiting a hospital in order to undergo additional tests and treatment.
• The doctor after taking into account the detailed medical history would carry out a physical examination and a particular kind of blood test that detects the count of all the varied forms of blood cells. If the outcome of the blood test reveals the presence of leukemia, then the doctor would extract a small sample of bone marrow for analysing the particular kind of leukemia present, which will assist in charting out the line of treatment.
• Bone marrow biopsy – Under the influence of local anaesthesia, a bone marrow sample is extracted with the help of a fine needle from the back of the pelvic area or the hip bone or infrequently from the sternum (breast bone) to be sent for microscopic analysis for detecting anomalous white blood cells. During the 15-20 minutes procedure performed in the ward or the outpatient facility, the needle is pierced through the skin all the way into the bone, following which a small bone marrow sample is removed into a syringe that could cause some level of pain or discomfort. A fast-acting sedation medicine would be given for allaying the pain during the test. At times, a small bone marrow core might be required for testing using a procedure known as trephine biopsy and could require a couple of minutes more. A special kind of needle is inserted through the skin till the bone marrow. The needle tip is tailored to incise out a sample of bone marrow. Bruising and aches might be felt subsequent to the test that could be lowered by taking mild pain-relieving medicines.
• Cytogenetic Testing – This test done on the blood and bone marrow involves chromosome testing to check for any specific alterations in the chromosomes, as varied kinds are linked with specific genetic alterations.
• Immunophenotyping – This test done on the blood and bone marrow sample reveals what kind of lymphocyte has turned malignant. Immunophenotyping could help in deciphering whether the leukemia originated from either B-lymphocytes or T-lymphocytes. Detecting what kind of lymphocyte has been affected, assists the doctors in charting out the most apposite treatment alternative.
• Chest x-ray – These are taken for checking whether there are any symptoms of inflamed lymph glands in the chest region.
• Lumbar puncture – Under the influence of local anaesthesia a small amount of cerebrospinal fluid sample is taken from the lower portion of the back via a needle injected till the spine. Lumbar puncture lasts for few minutes and might become painful. Few experience headache subsequently. The doctor would prescribe painkillers. Subsequently, one would be needed to lie down flat for a span of few hours.
• Other Scanning Procedures – An ultrasound, MRI and CT scans could be performed for detecting whether leukemia has metastasized to other body parts.

Acute Lymphoblastic Leukaemia Treatment:

Chemotherapy – Chemotherapy employs the use of cancer-combatant (cytotoxic) drugs for obliterating leukemia cells by interrupting their production. The drugs flow through the body after being intravenously administered. As these drugs are incapable of gaining entry into the cerebrospinal fluid (CSF), they need to be directly infused via a lumbar puncture. This is carried out in spite of leukemia cells not being spotted in the CSF, as research has revealed that there is definite possibility of some of the leukemia cells always been present in the CSF which would require eradication.

In men the drugs fail to reach the testes. Hence, additional treatment might become requisite when chemotherapy is given into the CSF that at times is merged with radiotherapy given to the brain. Radiotherapy might be given to the testes in men. Radiotherapy when given in this manner to the brain and the spinal cord or testes is called prophylactic radiotherapy.

Chemotherapy for treating acute lymphoblastic leukemia is offered in three varying phases, namely:

Induction

This is the foremost intensive treatment intended at wiping out major populace of the leukemia cells. It generally attains a reduction of the disease implying that the leukemia cells could not be henceforth spotted during microscopic analysis.

Drugs employed during this phase would comprise of daunorubicin, vincristine (Oncovin), methotrexate, cyclophosphamide, cytarabine (Ara C), mercaptopurine (Puri-Nethol). Steroids and drugs like allopurinol and folinic acid might additionally be given.

Intensification

At times, up to four intensive course of chemotherapy are generally offered to raise the probability of recovery. The drugs given in this phase could comprise of high-dosage methotrexate, vincristine, cytarabine, etoposide, daunorubicin, cyclophosphamide, tioguanine (Lanvis) and at times steroids might be given. Imatinib (Glivec) could be given to those having Philadelphia chromosome either alongside or as an alternative to chemotherapy during this phase.

Maintenance or Continual therapy

This tablet course of comparatively lesser intensive chemotherapy course is intended at obliterating any remnant leukemia cells. The drugs that might be used in this phase are mercaptopurine, methotrexate, vincristine, cytarabine (administered in the CSF). Steroids and antibiotics could also be given and Imatinib (Glivec) might be continued in this phase.

In case one is undergoing standard continual chemotherapy then the entire chemotherapy course would continue for at least 2 years. In case of high-dose chemotherapy following induction and intensification phase, the treatment would be shorter and last for lesser than a year.

How Is Chemotherapy administered?

Few drugs are given in pill form, but the key induction and intensification treatments comprise of a mixture of nearly 4 drugs given intravenously by two ways:

Central Line

In order to simplify the chemotherapy and to avert repeated injections, a fine pliable tube (central line) could be inserted into a vein in the chest under the influence of general /local anaesthesia via a small incision. The other tip of the tube is located outside the body with a facility to cap it when not in use. The tube is the conduit way for giving drugs, fluids, stem cells or bone marrow and for collecting blood samples.

Soreness and discomfort might be experienced for few days following the line being inserted, though the pain should subside thereafter. The line could remain for up to 2 years and the patient would be shown how to properly take care of the tube to avert any kind of blockages or infections.

PICC line and the implantable port

Optionally, a PICC line or an implantable port might be employed that is inserted into a vein in the crook of the arm.

Intrathecal chemotherapy

Chemotherapy mostly administered directly into the cerebrospinal fluid is known as intrathecal chemotherapy.

Side effects due to Chemotherapy

• Likelihood of easy and heavy bruising, bleeding , blood patches (petechiae) or rashes (purpura).
• Lowered immunity.
• Anaemia.
• Sense of unwell, weariness, oral sores.
• Hair loss.

Steroid Therapy

Steroids are drugs mostly administered alongside chemotherapy to assist in annihilating the leukemia cells. The two widely employed steroids are Prednisolone or dexamethasone. They are given in tablet form for just few days in a month. Hence, the associated side effects are fewer that include increased food craving, sense of greater energy and sleeplessness.

In case steroids are taken for some periods of time then the transitory side effects usually include bloating, high blood pressure, digestive disorders and a slight increase in the likelihood of contracting infections. The body’s blood glucose levels might also soar for which the doctor would recommend drugs for normalising the blood sugar levels.

Radiotherapy

Radiotherapy uses high-power beams for killing the cancerous growth while preserving as much as normal cells as possible. In cranial radiotherapy the treatment is given to the head. The treatment would be given for five days in a week lasting for 2 weeks and for 8 to 10 sittings.

In case one needs a high-dosage treatment alongside stem cell support, then a specialised form of radiotherapy known as total body irradiation or TBI is given. The radiotherapy is offered to the entire body to obliterate the bone marrow cells.

Initially for a couple of visits, x-rays of the areas to be treated would be taken by using a large device known as a stimulator.

In cranial radiotherapy, a transparent plastic mask shaped to the precise contour of the head and neck is fitted to maintain correct stance during the treatment. Marks are drawn on the mask for demarcating the treatment location.

In case the mask is not being used, the marks would be made on the skin and at times small permanent marks would also be made on the skin.

Radiotherapy does not cause any pain, however one would need to stay motionless during the few minutes the treatment lasts.

Side effects

• Hair loss.
• Extreme weariness.
• Sleepiness.
• Feeling nauseous and sick.
• Low appetite.

Imatinib (Glivec)

This drug as called as the signal transduction inhibitor (capsule form) could be used while treating those with Phildelphia chromosome positive ALL. Glivec functions by hampering signals within the leukemia cells that causes them to become irregular and continue to spread. By obstructing the signals, the cells face imminent death.

Glivec might lead to side effects like feeling unwell, at times diarrhoea, aches and cramps in the limbs, skin rashes, facial swelling particularly in the surrounding eye area.

High-dose Stem Cell Transplant

Stem cell transplant allows more elevated doses of chemotherapy to be given than what is normally given. Elevated chemotherapy doses, at times along with radiotherapy are given spanning a couple of days to aid in improving the likelihood of treating leukemia or to prolong a reduction in the disease.

The high-dose treatment is used in case the ALL has relapsed following treatment or is of a type that has high likelihood of recurrence following initial chemotherapy session.

The two means of carrying out the transplant is by:

• Making use of the own stem cells.
• Stem cells derived from a donor.